Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: "Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery | Schwenkglenks et al. Journal of Hematology Oncology 2010 3 27 http www.jhoonline.Org content 3 1 27 JOURNAL OF HEMATOLOGY ONCOLOGY SHORT REPORT Open Access Hodgkin lymphoma treatment with ABVD in the US and the EU neutropenia occurrence and impaired chemotherapy delivery 1 2 1 3 3 Matthias Schwenkglenks Ruth Pettengell Thomas D Szucs Eva Culakova Gary H Lyman Abstract Background In newly diagnosed patients with Hodgkin lymphoma HL the effect of doxorubicin bleomycin vinblastine and dacarbazine ABVD -related neutropenia on chemotherapy delivery is poorly documented. The aim of this analysis was to assess the impact of chemotherapy-induced neutropenia CIN on ABVD chemotherapy delivery in HL patients. Study design Data from two similarly designed prospective observational studies conducted in the US and the EU were analysed. One hundred and fifteen HL patients who started a new course of ABVD during 2002-2005 were included. The primary objective was to document the effect of neutropenic complications on delivery of ABVD chemotherapy in HL patients. Secondary objectives were to investigate the incidence of CIN and febrile neutropenia FN and to compare US and EU practice with ABVD therapy in HL. Pooled data were analysed to explore univariate associations with neutropenic events. Results Chemotherapy delivery was suboptimal with a relative dose intensity 85 in 18-22 of patients. The incidence of grade 4 CIN in cycles 1-4 was lower in US patients US 24 vs. EU 32 . Patients in both the US and the EU experienced similar rates of FN across cycles 1-4 US 12 vs. EU 11 . Use of primary colony-stimulating factor CSF prophylaxis and of any CSF was more common in the US than the EU 37 vs. 4 and 78 vs. 38 respectively . The relative risk RR of dose delays was 1.54 95 confidence interval CI 1.08-2.23 p 0.036 for patients with vs. without grade 4 CIN and the RR of grade 4 CIN was 0.35 95 CI 0.12-1.06 p 0.046 for patients with vs. without primary CSF prophylaxis. Conclusions In this